spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Signant Health Partners with Propeller Health to Gather Accurate Data on Asthma and COPD Medication Use

Signant Health


Signant’s TrialMax® eCOA platform and Propeller Health’s digital health platform connect to improve patient engagement and simplify data collection using real-time management and dose tracking


Philadelphia, PA – January 07, 2020: Signant Health announced today a partnership to connect TrialMax®, the industry-leading electronic Clinical Outcome Assessment (eCOA) platform, to Propeller Health’s digital health platform for asthma and COPD (chronic obstructive pulmonary disease).

The partnership will help drive patient adherence to inhaled medications by enabling accurate time tracking of patients’ medication use events alongside their eDiary data within a single eCOA platform. Sponsors, CROs, and academic institutions can use this information to identify how patients are following treatment plans and identify occurrences when symptoms are triggered, leading to better inhaler adherence, symptom control, and a simpler patient experience.

As always, TrialMax users benefit from a streamlined workflow presented intuitively in a single workspace. Sites and sponsors can view and report on medication use alongside clinical outcomes while study participants experience a simple and burden-free trial, as the Propeller sensors automatically track rescue and controller medication inhaler use. This level of insight allows researchers to track how populations are using inhalers, while still providing valuable insight to oversee the progress and care of individual patients as needed.

Bill Byrom, Signant Health’s VP Product Strategy & Innovation, said, “This integration is important in understanding inhaler use and patterns in patients with respiratory illnesses. This will enable researchers to relate medication usage to responses to treatment, and for site personnel to gain deeper insights together with eCOA data to enhance patient oversight between clinic visits, in addition to encouraging medication adherence where appropriate. The addition of the Propeller sensor within TrialMax’s ecosystem of connected wearables and sensors provides a frictionless way to collect medication usage data without requiring additional actions by the patient. The Propeller Health partnership is an important addition to our solutions for patient-facing technology to enhance data collection and insights in clinical trials in respiratory illnesses.”

Who Is Signant Health?
The best technology succeeds in the background. Signant Health provides solutions that simplify every step of the study participant journey to make it easier for people to participate in, and for sites and study teams to run, clinical trials. Signant unites eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite – an evolution built on more than 20 years of proven clinical research technology. Our intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable hundreds of sponsors and CROs (including all Top 20 pharma) to extend the reach of drug development, expand patient opportunities and improve data quality – helping them bring life-changing therapies to our families and communities around the world. Take a significant step toward patient-centricity at signanthealth.com.

+1 267.498.2350

phone +1 267 498 2300
email media@signanthealth.com
web https://signanthealth.com/
email 4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible Marc Hmel, CEO
More info >>


White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement